CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Spotlight Innovation Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Spotlight Innovation Inc
11147 Aurora Ave Bldg 3
Phone: (515) 274-9087p:515 274-9087 Urbandale, IA  50322-7904  United States
On March 29, 2016, management of Spotlight Innovation Inc., with the approval of the Board of Directors concluded that the previously issued financial statements contained in the Company's Quarterly Reports on Form 10-Q for the quarters ended June 30, 2014, September 30, 2014, March 31, 2015, June 30, 2015 and September 15, 2015 and in the Annual Report on Form 10-K for the year ended December 31, 2014 should no longer be relied upon because of an error in recording the value of intellectual property assets acquired in a transaction between the Company and Celtic Biotech Ltd., an Irish Limited Company, that closed on June 4, 2014. In the financial statements included in the Forms 10-Q and Form 10-K for the Prior Periods, the Company recorded intellectual property assets of $6,977,347 related to the Transaction. A subsequent valuation report dated March 29, 2016 indicated that the value that should have been recorded during the Prior Periods under generally accepted accounting principles should have been $415,579.
This company is no longer actively traded on any major stock exchange.
Business Summary
Spotlight Innovation Inc. is a pharmaceutical company. The Company is focused on acquiring the intellectual property rights to therapeutics designed to address unmet medical needs. As of June 30, 2017, the Company had four subsidiaries: Celtic Biotech Iowa, Inc. (Celtic Iowa), Caretta Therapeutics, LLC (Caretta), SMA Therapeutics, LLC (SMA), and Zika Therapeutics, LLC (Zika). It is focused on various diseases, including cancer, pain management, Zika Virus infection and spinal muscular atrophy. The Company, through Celtic Iowa, holds interest in Celtic Biotech Limited, which is engaged in developing specialized compounds derived from snake venom, for the treatment of solid cancers and cancer imaging. The Company, through Caretta, is focused on developing the commercialization of over-the-counter products. It is also engaged in discovery, synthetic modification, and preclinical validation of drug-like compounds intended to treat patients with Zika virus infection.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201812/31/2017YesYes-Yes-

Industries
SIC Code Description
1389 Oil and gas field services, not elsewhere classified
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Interim Chief Executive Officer, Interim Chief Financial Officer, John M.Krohn 10/8/2018 2/24/2016
Director RalphArthur 69 12/29/2016 12/29/2016
Director JuneBeetler 5/30/2017 5/30/2017

Business Names
Business Name
CDT Veterinary Therapeutics, Inc.
Celtic Biotech Iowa, Inc.
Celtic Biotech Ltd.
4 additional Business Names available in full report.

General Information
Outstanding Shares: 35,762,157 (As of 8/22/2018)
Shareholders: 33
Stock Exchange: OTC
Federal Tax Id: 980518266


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023